AXELYF, INC.
CHESTNUT HILL, MADeveloping the Next Generation of RNA Medicines Axelyf is advancing RNA medicines for oncology and autoimmune diseases — powered by AXL, a next-generation lipid nanoparticle platform validated for precise, potent delivery. Explore our Platform View Programs An Asset Development Company Built on Cutting Edge Delivery Science Axelyf is developing RNA therapeutics that address diseases where conventional approaches have fallen short. Our focus is on building and advancing proprietary drug candidates — starting with AX-004, our lead in vivo CAR-T program targeting solid tumors, and AX-003, targeting autoimmune hepatitis. Both programs are enabled by the AXL platform: a next-generation lipid nanoparticle delivery system validated in non-human primates and optimized with the help of ANNA™, our proprietary AI model for lipid design. Meet the Team Latest News
AI-driven lipid designdrug delivery sciencelipid chemistryRNA biologyRNA therapeutics development